Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus

Vaccine

Volumn 27, Issue 18, 2009, Pages 2513-2522

  Tiwari, Mugdha ^a   Parida, Manmohan ^a   Santhosh, S R ^a   Khan, Mohsin ^a   Dash, Paban Kumar ^a   Rao, P V Lakshmana ^a  

^a DEFENCE RESEARCH AND DEVELOPMENT ESTABLISHMENT   (India)

Author keywords

Chikungunya; Humoral and CMI response; Inactivated vaccine; Serum free medium; Spinner culture

Indexed keywords

ANTIBODY; CYTOKINE; FORMALDEHYDE; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; GENOTYPE; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MICROCARRIER CULTURE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERODIAGNOSIS; TH1 CELL; TH2 CELL; VACCINATION; VERO CELL; VIRUS INACTIVATION; VIRUS INFECTION; VIRUS PURIFICATION; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHIKUNGUNYA VIRUS; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FORMALDEHYDE; GENOTYPE; MICE; NEUTRALIZATION TESTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, ATTENUATED; VERO CELLS; VIRAL VACCINES;

EID: 62749169114     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.02.062     Document Type: Article

References (59)

1. Strauss J.H., and Strauss E.G. The Alphaviruses: gene expression, replication and evolution. Microbiol Rev 58 (1994) 491-562
2. Johnson R.E., and Peters C.J. Alphavirus associated primarily with fever and polyarthritis. In: Fields B.N., Knipe D.M., and Howley P.M. (Eds). Fields virology (1996), Lippincott-Raven Publishers, Philadelphia 843-898
3. Dash P.K., Parida M.M., Santhosh S.R., Verma S.K., Tripathi N.K., Ambuj, et al. East Central South African genotype as the causative agent in reemergence of Chikungunya outbreak in India. Vector Borne Zoonotic Dis 7 (2007) 719-727
4. Jupp P.G., and McIntosh B.M. Chikungunya virus disease. In: Monath T.P. (Ed). The arboviruses: epidemiology and ecology (1988), CRC Press, Florida 137-157
5. Rezza G., Nicoletti L., Angelini R., Romi R., Finarelli A.C., Panning P., et al. Infection with chikungunya virus in Italy: an outbreak in temperate region. Lancet 370 (2007) 1840-1846
6. Khan A.H., Morita K., Parquet Mdel C., Hasebe F., Mathenge E.G.M., and Igarashi A. Complete nucleotide sequence of Chikungunya virus and evidence for an internal polyadenylation site. J Gen Virol 83 (2002) 3075-3083
7. Schuffenecker I., Iteman I., Michault A., Murri S., Frangeul L., Vaney M., et al. Genome microevolution of chikungunya viruses causing the Indian Ocean outbreak. PLoS Med 3 (2006) e263
8. Tsetsarkin K.A., Vanlandingham D.L., McGee C.E., and Higg S. A single mutation in Chikungunya virus affects vector specificity and epidemic potential. PloS Pathogen 3 12 (2007) 0001-0012
9. Santhosh S.R., Dash P.K., Parida M.M., Khan M., Tiwari M., and Rao P.V.L. Comparative full genome analysis revealed A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res 135 (2008) 36-41
10. Porterfield J.S. Cross-neutralization studies with group A arthropod-borne viruses. Bull WHO 24 (1961) 735-741
11. Hearn H.J., and Rainey C.T. Cross protection in animals infected with group A arboviruses. J Immunol 90 (1963) 720-724
12. MacClain D.J., Pittman P.R., Ramsburg H.H., Nelson G.O., Rossi C.A., Mangiafico J.A., et al. Immunological interference from sequential administration of live attenuated alphavirus vaccines. J Infect Dis 177 (1998) 634-641
13. Eckels K.H., Harrison V.R., and Hetric F.M. Chikungunya virus vaccine prepared by Tween-Ether extraction. Appl Microbiol 19 2 (1970) 321-325
14. Harrison V.R., Eckels K.H., Bartellori P.J., and Hampton C. Production and evaluation of a formalin-killed Chikungunya vaccine. J Immunol 107 (1971) 643-647
15. Levitt N.H., Ramsburg H.H., Hasty S.E., Repik P.M., Cole Jr. F.E., and Lupton H.W. Development of attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4 (1986) 157-162
16. Eldeman R., Tacket C.O., Wasserman S.S., Bodison S.A., Aerry J.G., and Mgnifica J.A. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 62 6 (2000) 681-685
17. Pharmacia: microcarrier cell culture principal and method (1991), Pharmacia LKB Biotechnology, Uppsala, Sweden
18. Gould E.A., and Clegg T.C.S. Growth, assay and purification of Alphaviruses and Flaviviruses. In: Mahy B.W.J. (Ed). Virology: a practical approach (1991), Oxford University Press 43-48
19. Santhosh S.R., Parida M.M., Dash P.K., Pateriya A., Pattnaik B., Pradhan H.K., et al. Development and evaluation of SYBR Green I based one-step realtime RT-PCR assay for detection and quantification of chikungunya virus. J Clin Virol 39 (2007) 188-193
20. Dash P.K., Tiwari M., Santhosh S.R., Parida M.M., and Rao P.V.L. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Commun 376 (2008) 718-722
21. Russell P.K., Nisalak A., Sukhavachana P., and Vivona S. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99 (1969) 285-290
22. Borenfreund E., Babich H., and Martin A.N. Rapid chemosensitivity assay with human normal and tumor cells in vitro. In Vitro Cell Dev Biol 26 (1990) 1030-1034
23. Greiser-Wilke I.M., Moennig V., Kaaden O.-R., and Shope R.E. Detection of alphaviruses in a genus-specific antigen capture enzyme immunoassay using monoclonal antibodies. J Clin Microbiol 29 (1991) 131-137
24. Parida M.M., Upadhyay C., Saxena P., Dash P.K., Jana A.M., and Seth P. Evaluation of a Dipstick ELISA and a rapid immunochromatographic test for diagnosis of dengue virus infection. Acta Virol 45 (2001) 299-304
25. Pastorino B., Bessaud M., Grandadam M., Murri S., Tolou H.J., and Peyrefitte C.N. Development of a TaqMan RT-PCR assay without RNA extraction step for detection and quantification of African Chikungunya virus. J Virol Methods 124 (2005) 65-71
26. Laurent P., Le Roux K., Grivard P., Bertil G., Naze F., Picard M., et al. Development of a sensitive real-time reverse transcription PCR assay with an internal control to detect and quantify Chikungunya virus. Clin Chem 53 (2007) 1404-1414
27. Carletti F., Bordi L., Chiappini R., Ippolito G., Sciarrone M.R., Capobianchi M.R., et al. Rapid detection and quantification of Chikungunya virus by one-step reverse transcription-polymerase chain reaction real-time assay. Am J Trop Med Hyg 77 (2007) 521-524
28. Muthumani K., Lankaraman K.M., Laddy D.J., Sundaram S.G., Christiphar W.C., Eric S., et al. Immunogenicity of novel consensus-based DNA vaccine against Chikungunya virus. Vaccine 26 (2008) 5128-5134
29. Murphy B.R., and Chanock R.M. Immunization against viral diseases. In: Knipe D.M., Howley P.M., Griffin D.E., Martin M.A., Lamba R.A., Roizman B., et al. (Eds). Fields virology. 4th ed. vol. 1 (2001), Lippincott Williams and Wilkins, Philadelphia 435-467
30. Watson J.C., and Peter G. General immunization practices. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), WB Saunders Company, Philadelphia 47-73
31. Tasi T.F., Chang G.-J.J., and Yu Y.X. Japanese encephalitis vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), WB Saunders Company, Philadelphia 672-710
32. Barrett P.N., Dorner F., and Plotkin S.A. Tick-born encephalitis vaccine. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines. 3rd ed. (1999), WB Saunders Company, Philadelphia 767-780
33. Plesner A.M., and Ronne T. Allergic mucocutaneous reactions to Japanese encephalitis vaccine. Vaccine 15 (1997) 1239-1243
34. Sakaguchi M., Yoshida M., Kuroda W., Harayama O., Matsunaga Y., and Inouye S. Systemic immediate-type reactions to gelatin included in Japanese encephalitis vaccines. Vaccine 15 (2000) 121-122
35. Aunins J.G. Viral vaccine production in cell culture. In: Spier R.E. (Ed). Encyclopedia of cell technology vol. 2 (2000), John Wiley & Sons 1182-1217
36. Appaiahari M.B., and Vrati S. Immunogenicity and protective efficacy in mice of a formaldehyde inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine 22 (2004) 3669-3675
37. Montagnon B.J., Vincent-Falquent J.C., and Saluzzo J.F. Experience with Vero cells at Pasture Merieux Connaught. Dev Biol Stand 98 (1999) 137-140
38. Van Wezel A.L. Growth of cell strain and primary cells on microcarriers in homogeneous culture. Nature 216 (1967) 64-65
39. Spier R.E., and Kadouri A. The evolution of process for commercial exploitation of anchorage dependent animal cells. Enzyme Microb Technol 21 (1997) 2-8
40. Hesse F., and Wagner R. Developments and improvements in manufacturing of human therapeutics with mammalian cell cultures. Tibtech 18 4 (2000) 173-180
41. Fishbein D.B., Yenne K.M., Dreesen D.W., Teplis C.F., Mehta N., and Briggs D.J. Risk factors for systemic hypersensitivity reactions after booster vaccinations with human diploid cell rabies vaccine: a nationwide prospective study. Vaccine 11 14 (1993) 1390-1394
42. Swanson M.C., Rosanoff E., Gurwith M., Deitch M., Schnurrenberger P., and Reed C.E. IgE and IgG antibodies to beta-propiolactone and human serum albumin associated with urticarial reactions to rabies vaccine. J Infect Dis 155 5 (1987) 909-913
43. Froud S.J. The development, benefits and disadvantages of serum-free media. Dev Biol Stand 99 (1999) 157-166
44. Perrin P., Madhusudana S., Gontier-Jallet C., Petres S., Tordo N., and Merten O.W. An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system. Vaccine 13 (1995) 1244-1250
45. Merten O.W., Wu R., Couvé E., and Crainic R. Evaluation of the serum-free medium MDSS2 for the production of poliovirus on Vero cells in bioreactors. Cytotechnology 25 (1997) 35-44
46. Price P.J., and Evege E.K. Serum-free medium without animal components for virus production. Focus 19 (1997) 67-69
47. Merten O.W., Manuguerra J.C., Hannoun C., and Van der Werf S. Production of influenza virus in serum-free mammalian cell cultures. Dev Biol Stand 98 (1999) 23-37
48. Butler M., Burgener A., Patrick M., Berry M., Moffatt D., Huzel N., et al. Application of a serum-free medium for the growth of Vero cells and the production of Reovirus. Biotechnol Prog 16 5 (2000) 854-858
49. Wu S.C., Liu C.C., and Lian W.C. Optimization of microcarrier cell culture process for the inactivated enterovirus type 71 vaccine development. Vaccine 22 (2004) 3858-3864
50. Liu C.C., Lian W.C., Butler M., and Wu S.C. High immunogenic enterovirus 71 stains and its production using serum-free microcarrier Vero cell culture. Vaccine 25 (2007) 19-24
51. Simizu B., Yamamoto K., Hashimoto K., and Ogata T. Structural proteins of Chikungunya virus. J Virol 51 1 (1984) 254-258
52. Masuda N., Ohnishi T., Kawamoto S., Monden M., and Okubo K. Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples. Nucleic Acids Res 27 (1999) 4436-4443
53. Srivastava A.K., Putnak J.R., Lee S.H., Hong S.P., Moon S.B., Barvir D.A., et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19 (2001) 4557-4565
54. Thomas M.M., Park H., Fernadez-Sesma A., and Schulman J.L. Th-2 responses to inactivated Influenza virus can be converted to Th-1 responses and facilitate recovery from heterosubtypic virus infection. J Infect Dis 180 (1999) 579-585
55. Halstead S.B. Dengue. Lancet 370 9599 (2007) 1644-1652
56. Burton D.R., and Moor J.P. Why do we not have an HIV vaccine and how can we make one?. Nat Med 4 (1998) 495-498
57. Liu T., Zhou X., Orvell C., Lederer E., Ljunggren H.G., and Jondal M. Heat inactivated Sandai virus can enter multiple MHC class I processing pathways and generate cytotoxic T lymphocyte responses in vivo. J Immunol 154 (1995) 3147-3155
58. Pu R., Tellier M.C., and Yamamoto J.K. Mechanism(s) of FIV vaccine protection. Leukemia 11 (1997) 98-101
59. Victoratos P., Yiangou M., Avramidis N., and Hadjipetrou L. Regulation of cytokine expression by adjuvants in vivo. Clin Exp Immunol 109 (1997) 569-578